Article
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Apr 2022
Baek Grace, Jung Lindsey, Duong Arianne, Gralow Julie
Abstract excerpt
INTRODUCTION: Sacituzumab govitecan-hziy, approved in 2020 for treatment of metastatic triple-negative breast cancer, provides a new option for a population with a historically poor prognosis with standard chemotherapy. Uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizers are at increased risk for profound neutropenia. This case discusses clinical implications of the uridine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.